A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous CSL730 in Healthy Caucasian and Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2018
At a glance
- Drugs M-230 (Primary)
- Indications Autoimmune disorders; Epidermolysis bullosa
- Focus Adverse reactions
- Sponsors CSL Behring
- 21 Feb 2018 Status changed from not yet recruiting to recruiting, according to a Momenta Pharmaceuticals media release.
- 21 Feb 2018 According to a Momenta Pharmaceuticals media release, company began dosing subjects in in this trial and this trial is expected to complete in one year.
- 28 Dec 2017 New trial record